About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Safety and Efficacy of Xalkori ROS1

Safety and Efficacy of Xalkori ROS1

NCT03375242·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Pfizer

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

patients with unresectable progressive/recurrent NSCLC who are naive to XALKORI and whose tumor is ROS1 gene positive

You may not be if

Patients with past history of hypersensitivity to any of the ingredients of XALKORI

The record

StatusCompleted

PhaseNo phase

Taking part97

StartedOct 2017

UpdatedAug 28, 2026

Conditions

Non-small Cell Lung Cancer

Where1

Pfizer
Tokyo, Japan